News

May 7, 2025

MedVasc Selected to Present at Prestigious MedTech Pitch Day by HGTF 2025

One of Only 10 Startups Chosen from 86 Applicants to Pitch Before Leading Central European MedTech Investors Lund, Sweden, May 6, 2025 – MedVasc was selected to present at MedTech Pitch Day 2025, hosted by High-Tech Gründerfonds (HTGF), Germany’s largest investment fund for early-stage startups. Out of 86 high-potential…
May 7, 2025

MedVasc raises SEK 10 Million to accelerate final development and FDA preparation for Solutio™ device

Lund, Sweden – May 6, 2025 – MedVasc AB, a Swedish medical technology company  announces the successful closing of a SEK 10 million financing round earlier this year. The funding supports the company’s final product development phase and preparation for regulatory approval in the United States. The primary focus of the…
May 7, 2025

Dr. Michael Åkesson featured on stage at the American Venous Forum, Atlanta

Our founder Dr. Michael Åkesson was invited to present the results from our first-in-man clinical study at the American Venous Forum in Athens in February. We are very happy to see that there is such great interest from the Venous community and we look forward to bringing SolutioTM in to the hands of…
July 1, 2024

SolutioTM featured on stage at the European Venous Forum in Athens

Our founder Dr. Michael Åkesson was invited to present the results from our first-in-man clinical study at the European Venous Forum in Athens last week. We are very happy to see that there is such great interest from the Venous community – we look forward to bringing SolutioTM in to the…
May 24, 2024

Vinnova awards MedVasc a grant for a better understanding of reimbursement in the US

MedVasc has been awarded a grant of SEK 135,000 from Vinnova (Swedish Innovation Agency) to enhance the company’s understanding of the reimbursement landscape in the US. This support was secured through the Medtech4Health call 2024, aiming at strengthening small medtech companies through external competence. By the end of the…

For press inquiries, please send an email

Subscribe to our newsletter

For more information on how we process your personal data please see our Privacy Notice